Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.
作者信息
Gami Apoor S, Montori Victor M, Erwin Patricia J, Khan Mehmood A, Smith Steven A
机构信息
Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
出版信息
BMJ. 2003 Mar 8;326(7388):528-9. doi: 10.1136/bmj.326.7388.528.
Abstract
摘要
相似文献
1
Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.糖尿病患者冠心病一级预防中降脂治疗的系统评价
BMJ. 2003 Mar 8;326(7388):528-9. doi: 10.1136/bmj.326.7388.528.
2
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.降脂药物治疗糖尿病和非糖尿病患者的疗效：随机对照试验的荟萃分析
BMJ. 2006 May 13;332(7550):1115-24. doi: 10.1136/bmj.38793.468449.AE. Epub 2006 Apr 3.
3
Diabetes and lipids - a conundrum.糖尿病与血脂——一个难题。
Diabet Med. 2001 Mar;18(3):250. doi: 10.1046/j.1464-5491.2001.00436.x.
4
[Statins (HMG-CoA reductase inhibitors)].[他汀类药物（HMG-CoA还原酶抑制剂）]
Nihon Rinsho. 2006 Nov;64(11):2113-8.
5
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.斯堪的纳维亚辛伐他汀生存研究（4S）糖尿病受试者亚组分析：对冠心病预防的启示
Diabetes Care. 1997 Apr;20(4):469-71. doi: 10.2337/diacare.20.4.469.
6
Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?糖尿病患者的降脂治疗：应采用何种冠心病风险阈值？
Heart. 2002 May;87(5):423-7. doi: 10.1136/heart.87.5.423.
7
Managing lipid disorders: further evaluation of the VA-HIT.
Curr Diab Rep. 2003 Jun;3(3):245-7. doi: 10.1007/s11892-003-0071-4.
8
Lipid modification and coronary heart disease in type 2 diabetes: different from the general population?2型糖尿病中的脂质修饰与冠心病：与普通人群有别？
Heart. 1999 Jan;81(1):10-1. doi: 10.1136/hrt.81.1.10.
9
Coronary artery disease and diabetes.冠状动脉疾病与糖尿病。
Heart. 1997 Dec;78(6):527-8. doi: 10.1136/hrt.78.6.527.
10
Management of dyslipidemia in adults with diabetes. American Diabetes Association.成人糖尿病患者血脂异常的管理。美国糖尿病协会。
Diabetes Care. 1998 Jan;21(1):179-82. doi: 10.2337/diacare.21.1.179.
引用本文的文献
1
Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review.高甘油三酯血症诱发的复发性急性胰腺炎：基于病例的综述
Indian J Endocrinol Metab. 2012 Jan;16(1):141-3. doi: 10.4103/2230-8210.91211.
2
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.非诺贝特：一种用于治疗脂质紊乱的新型制剂（力平之）：综述
Int J Nanomedicine. 2006;1(2):129-47. doi: 10.2147/nano.2006.1.2.129.
3
Creating a conversation: insights from the development of a decision aid.开展对话：决策辅助工具开发的见解
PLoS Med. 2007 Aug;4(8):e233. doi: 10.1371/journal.pmed.0040233.
4
Hypertriglyceridemia: its etiology, effects and treatment.高甘油三酯血症：其病因、影响及治疗
CMAJ. 2007 Apr 10;176(8):1113-20. doi: 10.1503/cmaj.060963.
5
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).阿托伐他汀用于2型糖尿病患者心血管疾病一级预防的成本效益：阿托伐他汀糖尿病协作研究（CARDS）结果
Diabetologia. 2007 Apr;50(4):733-40. doi: 10.1007/s00125-006-0561-4. Epub 2007 Jan 31.
本文引用的文献
1
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).国家胆固醇教育计划（NCEP）成人高血胆固醇检测、评估与治疗专家小组第三次报告（成人治疗小组第三次报告）执行摘要
JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
Zotero 插件